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 Cytochrome P450 enzymes in the liver catalyze reactions involving the reduction 
of molecular oxygen and the oxidation of organic substrates.  In some cases the resuling 
products may have the potential to contribute to oxidative stress within this organ.  
Oxidative stress usually involves the generation of very reactive compounds that can 
damage cellular components and are therefore harmful to the body. These reactive
compounds can include hydrogen peroxide, superoxide, hydroxyl radicals, and a host of 
other metabolic intermediates (1).  Oxidative stress occurs in alcoholics in the liver when 
an individual consumes harmful amounts of alcohol which can lead to the production of 
any one or more of the compounds listed above (2).     
 Cytochrome P450 enzymes have been linked to increased development of 
oxidative stress in the liver of alcoholics (2).  Cytochrome P4502E1 (CYP2E1) can cause 
mitochondrial stress and disruption via hydrogen peroxide productions which disturbs 
signaling pathways between cells (3).  On the other hand, Cytochrome P4502A6 
(CYP2A6) has been shown to activate several known potent carcinogens found in 
tobacco smoke (4).  Cytochrome P4503A4 (CYP 3A4) is a widely recognized enzyme that 
plays a major role in the metabolism of pharmaceutical drugs, in fact more than 50% of
all drugs are metabolized by this enzyme.   
 This study was designed to attempt to expand the knowledge of Cytochrome P450 
inhibition by this series of citrus essential oils by studying their effects on Cytochrome 
P4502E1, Cytochrome P4503A4 and Cytochrome P4502A6.  Here the goal was to determine 
 
 
if any of the nine citrus essential oils would inhibit any of the three Cytochrome P450 
enzymes and if so then it would be determined how potent each citrus essential oil is and 
by what type of inhibition it occurred and determine the correlation between limonene, 
the main component in each citrus essential oil, and potency of each citrus essential oil.  
The results for CYP2E1 concluded that Ci rus tangerine, tangerine, with a KI value of 4 
µg/mL was the most potent inhibitor and Citrus aurantium, neroli, with a KI value of 14 
µg/mL was the least potent inhibitor.  The results for CYP3A4 concluded that none of the 
nine citrus essential oils inhibited the activity of CYP3A4 at a good quality concentration.  
Lastly, the results for CYP2A6 concluded that both Citrus bergamia, bergamot, and 
Citrus aurantifolia, lime, were the most potent inhibitors with a KI of 0.81 µg/mL and a 
K I of 1.4 µg/mL.  It was concluded that bergamot oil contained 3.46 mM of limonene, 
grapefruit had 7.84 mM, lemon 4.24 mM, lime 3.75 mM, mandarin 3.79 mM, neroli 4.14 
mM, orange 6.65 mM, and tangerine had 5.92 mM of limonene.  Petitgrain oil was the 
only oil that a limonene concentration was unable to be detected, which is expected 
according to literature reviews which say petitgrain oil only has a 1-2 % content of 
limonene.   
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CHAPTER I 
INTRODUCTION 
 Cytochrome P450 enzymes catalyze reactions involving the reduction of 
molecular oxygen and the oxidation of organic substrates.  These reactions can result i
the production of compounds that may have the potential to contribute to oxidative stress 
within the liver or whatever tissue is exposed.  Oxidative stress involves the generation of 
reactive compounds that can damage cellular components.  These reactive compounds 
can include hydrogen peroxide, superoxide, hydroxyl radicals, and a host of other 
metabolic intermediates (1).  Ethanol has been implicated in the induction of oxidative 
stress by increasing the amount of Cytochrome P4502E1 (CYP 2E1) in the liver (5) and it 
has been shown that CYP 2E1 can cause mitochondrial stress and disruption via 
hydrogen peroxide production which disturbs signaling pathways between cells (3).  
Cytochrome P4502A6 (CYP 2A6) has been shown to activate several known potent 
carcinogens found in tobacco smoke (4) and Cytochrome P4503A4 (CYP 3A4) is a widely 
recognized enzyme that plays a major role in the metabolism of more than 50% ofall 
pharmaceutical drugs on the market (6). 
The purpose of this study was to attempt to expand the knowledge of Cytochrome 
P450 inhibition by a series of citrus essential oils by studying their effects on CYP 2E1, 
CYP 3A4 and CYP 2A6.  The goal was to determine if any of the nine citrus essential 
oils would inhibit any of the three CYP450 enzymes and if so then it would be 
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determined how potent each citrus essential oil was and what type of inhibition 
occurred.An additional goal was to establish a link between the inhibition and certain 
known constituents of the oils such as limonene, which is the main component in each 
citrus essential oil, and potency of each citrus essential oil.  The significance of this 
research is that if the oils inhibited the CYP450 activity it could prevent the production of 
reactive oxygen species (ROS) within the liver, where the enzymes reside.  Each enzyme 
had a specific substrate that was used to monitor activity and to detect the amount of 
inhibition that was caused by each of the oils.  Inhibition was analyzed using High 
Performance Liquid Chromatography (HPLC) and several methods were developed for 
more effective analysis.  The amount of limonene in each oil was determined to establish 
if there the correlation between its content and the potency of the inhibitor.  This was 
determined by using Gas Chromatography-Mass Spectrometry (GCMS).   
I. A. Cytochrome P450 Enzymes 
 Cytochrome P450 enzymes (CYP450) are the most common Phase I enzymes.  
Phase I enzymes are drug metabolizing enzymes that are responsible for the metabolism, 
elimination, and/or detoxification of xenobiotics that enter the body through ingestion of 
food, beverages, drugs,  natural products, cosmetics, and/or tobacco products (7).  These 
enzymes are part of a very large family of hemeproteins that are made up of different 
families and subfamilies and are found in different spices including mammals, plants, and 
bacteria (8).  Figure I. 1 illustrates the heme iron III center that takes part in catalysis.  
As seen in this figure, the iron III center is bound to the nitrogens in the four surrounding 
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pyrrole rings and covalently bound to the sulfur in the cysteine ligand.  Not shown in this 
figure is the sixth ligand that is bound to the iron III center which is a water molcule.   
 
 
 
Figure I. 1:  Cytochrome P450 prosthetic heme iron III center showing the covalent bond 
between the iron III center and the sulfur of the cysteine ligand.  Also shown are side 
chains, four pyrrole rings labeled A-D, and the four nitrogen ligands surrounding the iron 
III center (8). 
 
 
They are classified based on their similarities of their amino acid sequences identities and 
are located throughout the human body in the lungs, gastrointestinal tract, and kidneys, 
however they are most abundantly found in the liver (7).  Many CYP450 enzymes 
catalyze a monooxygenase reaction in which the substrate (RH) gets one oxygen from 
molecular oxygen (O2) incorporated into it (ROH) and the other oxygen forms a water 
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molecule (H2O) with the input of two protons (2H
+) and two electrons (2e) as shown in 
Equation I. 1 (8). 
RH + O2 + 2H
+ +2e-  ROH + H2O  Equation I. 1 
 The CYP450 catalytic cycle involves the reaction of the iron III center with a 
substrate, two electrons, two protons, and molecular oxygen.  It begins the CYP450 in its 
resting state with the iron III (ferric iron) center in a low-spin state with all six of its 
ligands bound.  When the substrate binds to the enzyme the water molecule is removed 
and the ferric iron center spin-state is changed to high-spin (9).  This step i  a result of the 
d orbital splitting where the low-spin state has one unpaired electron and change of 
symmetry to the ferric iron center when the water molecule is displaced changes the spin 
state to a high-spin state with 3 unpaired electrons (Figure I. 2).   
 
 
 
Figure I. 2:  Spin states of the iron III center.  Top: Low-spin state of the resting state of 
CYP450.  Bottom:  High-spin state after the water molecule has been displaced and the 
substrate is bound.   
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Figure I. 3 demonstrates the Catalytic cycle of CYP450.  The first step (substrate 
binding) triggers the conversion of the low spin (LS) ferric iron III center of CYP450 to a 
high spin (HS) iron III center.  Once the substrate is bound the redox potential is lowered 
and the ferric iron center can now be readily reduced to a ferrous iron II state via el ctron 
transfer from a reduced flavoprotein (CYP450 reductase) which accepts electrons from 
NADPH (step 2).  In the ferrous iron state the iron II center binds to molecular oxygen 
due to its high affinity to bind and the same high-spin states of molecular oxygen and the 
iron II center (step 3).  This step changes the spin-state back to low-spin where the 
ferrous iron bound to the oxygen is stabilized by resonance with an electron-transfer from 
the ferrous iron to the oxygen complex creating a ferric-superoxide (step 4).  A second 
electron is transferred from the flavoprotein generating a ferrous superoxide complex 
(step 5), which is in resonance with the ferric peroxo complex (step 6).  To finish the 
CYP450 catalytic cycle the now ferric-peroxo-complex is converted to a highly reactive 
oxoferryl intermediate with the addition of the two protons (step 7) (1), and in the 
presence of substrate, this species catalyzes the transfer of oxygen to the substrate 
regenerating the resting ferric state.   
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Figure I. 3:  Cytochrome P450 catalytic cycle showing the various oxidative states of the 
iron heme center and the spin states of the iron heme center.   
 
 
 
In the absence of substrate, a non productive release of H2O2 can also occur as shown in 
(Figure I. 4).   
 
 
 
Figure I. 4:  The two different pathways that can occur in the CYP450 catalytic cycle.  
Top: Productive pathway in which water is bound to the ferric iron center and the 
oxygenated substrate is formed.  Bottom: Nonproductive pathway in which hydrogen 
peroxide is formed and dissociates from the ferric iron center. 
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The nonproductive pathway is a side reaction that occurs when uncoupling takes place 
within the cycle releasing the ferric iron center in high-spin and hydrogen peroxide, ROS.  
It can also occur when the substrate binding, oxygen binding, and electron delivery are 
not coordinated during the catalytic cycle (10).  Hydrogen peroxide can then decompose 
into two hydroxyl radicals (Equation I. 2) which also causes oxidative stress.   
    H-O-O-H  2HO•  Equation I. 2 
I. B. Cytochrome P450 2E1 
 Cytochrome P450 2E1 (CYP 2E1) is located in the liver but can also be found in 
the brain, lungs, and a variety of other tissues, thus CYP 2E1-induced oxidative stress can 
be a global problem in the human body.  CYP 2E1 has been studied for its ability to 
metabolize ethanol, activate procarinogens, and its relationship to alcoholism, diabetes, 
and other diseases (10).  In addition to H2O2 production, CYP 2E1 can generate toxic and 
carcinogenic compounds via activation of a number of pro-carcinogens (10).  It has been 
shown that the levels of CYP 2E1 are highly elevated in the liver of alcoholics (11), 
which may contribute to the pathology of alcoholic liver disease.  CYP 2E1 only plays 
about a 4% role in the metabolism of drugs, however its ability to metabolize 
carcinogens, organic solvents, industrial chemicals, and other toxins such as ethanol, 
benzene, lauric acid, acetone, and more make it a particularly good target for 
toxicological study (12).   
 CYP 2E1 is known to metabolize para-nitrophenol (p-NP) into nitrocatechol with 
a high binding affinity.  The substrate p-nitrophenol is therefore a convenient probe fo  
CYP 2E1 activity and was used to detect CYP 2E1 activity in this study.  Figure I. 5 
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shows the reaction catalyzed by CYP 2E1 which oxidizes p-nitrophenol forming 
nitrocatechol.   
 
 
OH
NO2
OH
NO2
OH
p-nitrophenol nitrocatechol
CYP 2E1
 
Figure I. 5:  CYP 2E1 catalyzed reaction of the oxidation of p-nitrophenol to 
nitrocatechol.    
 
 
 
I. B. i. CYP 2E1 Active Site 
 The active site of CYP 2E1 is relatively hydrophobic and small compared to mos 
CYP450s.  It is so small that it is one of the smallest active sites that has been discovered 
for CYP450 enzymes.  P. R. Porubsky and colleagues have shown that the CYP 2E1 
active site has two adjacent voids, one which is enclosed above the I helix and the other 
forms a channel to the protein surface.  The volume of the active site is around 190 Å 
which explains why substrates for CYP 2E1 have low molecular weights.  The amino
acids that line the active site on the successive turn of the I helix are Ala299 and Thr303.  
The opposite side of the active site consists of an intersection of residues in and near the 
B’ helix, which includes Phe106, Ile115, and Phe116, the loop between helix K and β1–4, 
which includes Val364 and Leu368, and the β4–1, / β4–2, turn, Phe478.  There are five 
phenylalanine residues, Phe106, Phe116, Phe207, Phe298, and Phe478, which line the 
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roof of the active site (Patrick R. Porubsky, 2008).  There is also an enclosed cavity that 
is located adjacent to the active site that has a volume of 77 Å and is formed by the amino 
acids His109, Leu202, Phe203, Asn206, Val239, Val242, Lys243, Ala294, and 
Asp295 (10).  CYP 2E1 also has an access channel orientated adjacent to the active site 
opposite of the I helix and extending to the surface.  It contains several water molecules 
and is separated from the active site by Phe478.  Rotation of Phe478 residue would allow 
compounds to have direct communication with the active site.  F gure I. 6 shows four 
different views of the active site (10).   
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Figure I. 6:  Stereo views CYP 2E1 active site showing the ligand containing active site, 
small distal void, and access channel.  Figure displays cavities, B’ helix and adjcent 
loop, F helix, G helix, I helix, loop between K and β1-4, and β4-1/β4-2 turn.  Top: access 
channel is omitted.  Bottom: F helix is omitted (10).   
 
 
The compounds that enter the active site of CYP 2E1 are restricted by the size of the 
active site, thus only low molecular weight compounds are able to enter the active site.  
The nonpolar phenylalanine residues that line the roof of the active site interact with 
aromatic compounds which explains why p-NP, an aromatic low molecular weight 
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compound, is a favorable substrate for CYP 2E1.  Figure I. 7 shows the orientation of p-
NP in the active site of CYP 2E1 (11).  The residues that interact with p-NP are Phe478, 
Leu368, Thr303, and Ala299 as well as the heme iron center.  Residues Val364, Pro365, 
Ser366, Asp367 and Leu368 have stabilizing interactions with p-NP (11).   
 
 
 
Figure I. 7:  Structure of CYP 2E1 with p-nitrophenol bound in the active site showing 
the amino acid residues involved in the reaction (11).  
 
 
 
I. B. ii. CYP 2E1 Role in Alcoholics 
 Ethanol-induced oxidative stress has been shown to play a major role in the 
mechanism by which ethanol causes liver damage.  The CYP 2E1 pathway contributes to 
the ability of ethanol to induce oxidative stress by metabolizing and activating ethanol to 
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a more reactive and toxic product acetaldehyde.   It has been shown that a decrease in 
CYP 2E1 induction was associated with a reduction in alcohol-induced liver damage (5).  
Diallyl sulfide, phenethyl isothiocyanate, and chlormethiazole have been shown to inhibit 
CYP 2E1 (5).  Autoantibodies against CYP 2E1 have been discovered in the liver of 
alcoholics that recognize hydroxyl radicals (13), further illustrating the significance of 
this mechanism for oxidative damage resulting from the CYP 2E1 enzyme.  These 
observations suggest that CYP 2E1 inhibitors may represent a viable therapeutic tool to 
prevent oxidative stress.   
I. C. Cytochrome P450 3A4 
Cytochrome P450 3A4 (CYP 3A4) is located mainly in the liver but can also be 
found in the small intestines, lungs, stomach, and colon.  Other CYP 3A subfamily 
enzymes can be produced in the kidneys, prostate, testis and thymus however the 3A4 
isoform is not.  It is the most abundant CYP450 enzyme in the human body metabolizing 
around 30% of all drugs which is more than any other CYP450 enzyme (13).  It has been 
discovered that in fetal livers the most abundant enzyme is CYP 3A7 and CYP 3A4 is 
expressed at low levels.  After birth the expression of CYP 3A4 increases rapidly and 
reaches 50% of adults level expression at the age of 6 to 12 months after birth (13).  CYP 
3A4 has been shown to have at least three binding sites (14). 
CYP 3A4 is known to metabolize nifedipine into oxidized nifedipine, thus the 
substrate nifedipine is a useful marker used to probe CYP 3A4 activity.  This substrate 
was therefore used in the current study to monitor inhibition.  It should be noted also, that 
the rabbit produces a related isoform CYP 3A6 that can be used as a model for the human 
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CYP 3A4 enzyme, with very similar catalytic activities.  The current study utilizes rabbit 
tissue rather than human tissue.  Figure I. 8 shows the reaction catalyzed by CYP 3A4 
which oxidizes nifedipine forming oxidized nifedipine.   
 
 
NO2
N
OCH3
O
CH3CH3
H3CO
O
NO2
N
H
OCH3
O
CH3CH3
H3CO
O
nifedpine oxidized nifedipine
CYP 3A4
 
Figure I. 8:  CYP 3A4 catalyzed reaction of the oxidation of nifedipine to 
oxidized nifedipine.    
 
 
I. C. i. CYP3A4 Active Site 
 The active site of CYP 3A4 is very large and hydrophobic.  The size of the active 
site is why CYP 3A4 is able to metabolize a broad range of compounds with very high 
molecular weights.  Due to the lipophlic character of the active site hydrophobic 
interactions are largely responsible for substrate binding (15).  The volume of the active 
site is around 600 Å in size.  The active site of CYP 3A4 is made up of many different 
amino acids but the amino acids that form the catalytic center of CYP 3A4 and have a 
role in substrate binding are Leu210, Leu211, and Asp214.  These amino acids residues 
are located in the F-helix which is isolated from the iron heme center (15).  Figure I. 9 
shows two different views of the active site of CYP 3A4.  The active site of CYP 3A4 
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consist of five substrate channels, 2a, 2b, 2c, 2e, and 3 and one solvent channel, S.  These 
channels are defined depending on the secondary structure that exhibits the entrancea d 
exit of the channel.  Channel 2a is located in the active site of CYP 3A4 between the FF’ 
loop and the β1 sheet and β4 sheet and has a length of 19 Å.  Channel 2b has a length of 
18 Å and is situated between the F’ helix, G’ helix and the β1 sheet and the BC loop.  
The 2c channel has a length of 17 Å and is positioned between the GG’ helix and the BC 
loop and channel 2e is beside the BC loop as well with a length of 12 Å.  Channel 3 
passes through the F’ helix as well as the G’ helix with a length of 17 Å and the S 
channel is located above the I helix and between the FF’ loop and the β4 sheet with a 
length of 13 Å (16).   
 
 
 
Figure I. 9:  Secondary structures of the active site of CYP 3A4 showing the different 
helices, β-sheets, loops and channels.  Left: FF’loop, F’ helix, G’ helix, G helix, I helix, 
BC loop, β1 sheet, and β4 sheet.  The heme iron center is white.  Right: Channel surfaces; 
channel 2a, channel 2b, channel 2c, channel 2e, channel 3, and channel S.  F’ and G’ 
helices are shown as well as the BC loop. (16).   
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The orientation and the interactions for the substrate nifedipine and the active site of CYP 
3A4 are highly specific.  The nitro group on nifedipine forms a hydrogen bond with the 
amino acid residue Ser113.  This hydrogen bond, together with other interactions with 
active site amino acid residues, help position nifedipine for the N-oxidation reaction it 
undergoes.  The hydrogen that is attached to the nitrogen ring is oriented so that it lies 
directly above the heme iron center (17).   
I. C. ii. CYP 3A4 Role in Drug Metabolism 
 CYP 3A4 enzymes pose a problem in drug development and clinical use of drugs 
because of its interactions with drug disposition and/or drug-drug interactions.  CYP 3A4 
metabolizes a high percentage of drugs that enter the human body.  A high level of 
enzyme activity toward a drug causes a decrease in that drugs bioavailability (13) 
conversely, drugs, or compounds, that inhibit this isoform can reduce the normal 
metabolism of another drug, causing elevated levels and potential toxic side effects.  It 
has been reported that the interaction between CYP 3A4 and herbal medicines is one of 
the worst problems that CYP 3A4 enzymes cause.  Saint John’s Wort interactions wih 
CYP 3A4 has been one of the most studied relationships.  Saint John’s Wort increases the 
activity of CYP 3A4 which in turn decreases the effectiveness of oral contraceptives (18).   
I. D. Cytochrome P450 2A6 
 Cytochrome P450 2A6 (CYP 2A6) is mainly found in the liver but can also be 
found in other tissues including trachea, lung, nasal mucosa, and esophageal mucosa.  
However, it is expressed at medium to low levels in the human liver.  CYP 2A6 
metabolizes less than 5% of all drugs and is studied for its effect in liver cancers (13).  
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CYP 2A6 is also responsible for the detoxification of nicotine in the human body and for 
the activation of tobacco specific carcinogens (19).   
 CYP 2A6 is the only CYP 450 enzyme known to catalyzes the 7-hydrooxylation 
of coumarin.  Coumarin is therefore the ideal compound to probe for the activity of CYP 
2A6 (13).  Figure I. 10 shows the reaction catalyzed by CYP 2A6 which is the 7-
hydroxlyation of coumarin.   
 
 
O O O OOH
CYP 2A6
coumarin 7-hydroxycoumarin  
 
Figure I. 10: CYP 2A6 catalyzed reaction of the hydroxylation of coumarin to 7-
hydroxycoumarin.    
 
 
 
I. D. i. CYP 2A6 Active Site 
 The active site of CYP 2A6 is small, compact, and hydrophobic (20).  It is the 
most abundant of the three members of the CYP 2A subfamily (21).  CYP 2A6s active 
site has only one amino acid that is able to be a hydrogen bond donor, Asn297.  Asn297 
is the amino acid that orientates the coumarin substrate so that it is able to be oxidiz d 
properly (20).  Asn297 is orientated in the proper direction with help from its neighborng 
amino acids (20).  Another important interaction between the amino acids in the active 
site and the substrate is the interaction between Phe107 and aromatic or planar substrate , 
which help s to explain selectivity of this enzyme.  Other amino acids that line the activ  
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site of CYP 2A6 include Tyr114, Gly115, Phe118, Val117, and Met293.  The compounds 
that enter the active site of CYP 2A6 are compounds that are small planer and adapte  for 
oxidation (19).  Coumarin is the ideal substrate for CYP 2A6 and has been shown to only 
be metabolized by CYP 2A6 (13).  The active site of CYP 2A6 binds with coumarin in a 
specific way with a hydrogen bond between Asn297 and coumarin which orientates 
coumarin for the 7-hydroxylation reaction that it undergoes.   
I. D. ii. CYP 2A6 Role in Tobacco Users 
 Tobacco use has been associated with cancers for a long time.  Including cancers 
of the lung, larynx, mouth, esophagus, kidneys, and urinary tract.  The CYP450 enzymes 
are able to metabolize tobacco carcinogens into DNA-binding metabolites (22), in 
particular, nitrosamines.   CYP 2A6 enzymes also play a role in catalyzing the 
metabolism of many environmental chemicals including coumarin, nicotine, and several 
tobacco-specific carcinogens (23).  For example, CYP 2A6 are the main catlyst involved 
in the metabolism of nicotine to cotinine via 3’-hydroxylation (13).  The inhibition of 
CYP 2A6 has recently been identified as a possible therapeutic approach to smoking 
cessation, thus giving significance to the current study, whose goal is to identify natural 
products with the ability to inhibit this isoform.  Of significance also is the fact that 
inhibition of CYP 2A6 may reduce the ability of this enzyme to activate pro-carcinogens 
into carcinogenic products.  For example CYP 2A6 also catalyzes the 2’-hydroxylati n of 
nicotine which is a known precursor of lung carcinogens (13).  It has been shown that 
individuals who lack the CYP 2A6 enzyme have impaired nicotine metabolism and may 
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be protected against tobacco dependence (22), and possibly some of the carcinogenic 
effects of these products.      
I. F. Citrus Essential Oils 
The most commonly known fact about essential oils is that they are used during 
massages, for aromatherapy and used as food additives.  An essential oil is the volatile 
lipid-soluble portion of the fluids of a plant that contains odiferous compounds (24).  
Such fluids are produced through steam distillation of the plant matter which can be any
part of the plant including the stem, branch, fruit, flower, leaf, seed, root, bark, etc.  
Essential oils are made up of hundreds of compounds and are very complex substances.  
One thing that citrus essential oils have in common is that they all have the compound 
limonene present in them.  Table I. 1 shows the literature research results of the amount 
of limonene found in different citrus essential oils.   
 
 
 
Oil % Limonene 
Limonene 95% 
Grapefruit 86-92 % 
Orange 85-90 % 
Tangerine 65-80 % 
Mandarin 65-75 % 
Lemon 55-75 % 
Lime 34-64 % 
Bergamot 25-40 % 
Neroli 9-18 % 
Petitgrain 1-2 % 
 
Table I. 1:  Literature results of the total content of limonene found in citrus essential 
oils grapefruit, orange, tangerine, mandarin, lemon, lime, bergamot, neroli, and 
petitgrain.   
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I. F. i. Role in Humans 
There are four common ways to ingest essential oils, through inhalation by the 
lungs, absorbance through the skin, through the digestive tract from oral administratio , 
and from absorbance of our bodies’ orifices (24).  There are different opinions of the best 
ways to administer essential oils.  According to David Stewart, who wrote  “The 
Chemistry of Essential Oils: Made Simple”, Germans think inhalation through the lungs
is the most effective way to obtain the benefits of essential oils, the English think 
absorbance through the skin from messages is the most effective, and the French think 
that taking them orally is the most effective.  Over 95% of essential oils are produced for 
flavoring of foods and fragrances for perfumes.  In humans essential oils can be used as a 
nutritional supplement such as borage oil, coconut, garlic, etc.  An advantage that 
essential oils have is that the compounds that make them up are very small and can 
therefore easily enter by our bodies.  The essential oils also act as competitive inhibitors 
which is when a reversible inhibitor binds to the active site of an enzyme taking the place 
of the substrate and competing with the substrate for binding (25).  Mitsuo Miyazawa, et 
al have reported studies that show CYP450 enzymes are responsible for the metabolism 
of limonene in animals such as rats, mice, rabbits, guinea pigs, and even dogs.  The 
CYP450 enzymes located in liver microsomes from these animals oxidize limonene t  
different oxidized products including 1,2-epoxides, 8,9-epoxides, a 6-hydroxylation 
which produces carveol, and a 7-hydroxylation which produces perillyl alcohol (26).  
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In the current study we have examined the ability of a variety of citrus essential 
oils to inhibit the activities of CYP 2E1, 3A6, and 2A6.  Essential oils are natural 
products that are presumed to be safe for human consumption.  Essential oils could be an 
important class of products for reducing oxidative stress because of the compounds found 
in them and what they are able to do.  For example, compounds such as bergaptol and 
geranylcoumarin, found in grapefruits, act as radical scavengers (27).  Essential oil 
components such as linalol, linalyl acetate, and monoterpene esters have shown to have 
beneficial effects to human health by acting as an anti-inflammatory (28). Studies have 
also shown that essential oils have antibacterial effects.  For example, when added to 
mouthwash essential oils cause cell lysis in the organisms that are responsible for plaque 
and gingivitis (29).  Essential oils have strong activity against the Gram-positive 
microbes that cause plaque and gingivitis. There have also been reports that show that 
essential oils have mild antifungal effects however they are not as strong as antibiotics 
(30).  Essential oils have the potential to reduce the production of H2O2, OH radicals and 
the activation of carcinogens by CYP 2E1 enzymes, reduce drug interactions by CYP 
3A4 enzymes, and act as a possible therapeutic approach to smoking cessation and as an 
anti-cancer agent by inhibiting CYP 2A6 activity.
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CHAPTER II 
EXPERMIENTAL 
II. A. Reagents: Source of all Purchased Chemicals 
 The chemicals that were used during these studies were purchased from different 
companies.  The p-nitrophenol, nitrocatechol, nifedipine, coumarin, 7-hydroxycoumarin, 
and limonene were purchased from Sigma-Aldrich.  Oxidized nifedipine was purchased 
from Oxford Biomedical.  The human liver microsomes that were used in the CYP 2E1 
assays was purchased from Moltox in Asheville, North Carolina and the rabbit livers 
were purchased from Pel-Freeze in Rogers, Arkansas.  The citrus essential oils were 
purchased from Birch Hill Happenings Aromatherapy, LLC in Barnum, Minnesota.    
II. A. i. Preparation of Microsomes 
 Rabbit liver microsomes were generated in the lab using whole rabbit livers.  The 
rabbit livers were first homogenized in a 50 mM potassium phosphate buffer, pH 7.4, 
which contained 0.1 mM EDTA.  Once homogenized, the mixture was centrifuged using 
a JA-10 centrifuge rotor at 4420 x g for 10 minutes at 4°C.  The pellet in the mixture was 
discarded and the supernant was centrifuged using a JA-20 centrifuge rotor at37000 x g 
for 60 minutes at 4°C.  Lastly, the pellet was resuspended in a minimal volume of the 
homogenization buffer described above.  Microsomes were then separated into 200 µL 
aliquots and stored at -80°C. 
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II. B. CYP 2E1 Assays and Conditions 
 Enzyme kinetics studies have been used to look at the effects of citrus essential 
oils on CYP2E1.  The oils include Citrus bergamia, Citrus paradisi, Citrus limon, Citrus 
aurantifolia, Citrus reticulata, Citrus aurantium, Citrus sinensis, Citrus aurantium, and 
Citrus nobilis.  These oils are also commonly known as bergamot, grapefruit, lemon, 
lime, mandarin, neroli, orange, petitgrain, and tangerine.  Limonene was also evaluated 
for its effect on CYP 2E1.   
II. B. i. Initial Screening Assay for CYP 2E1 
The assay that was used to measure the amount of inhibition of CYP 2E1 
involved the oxidation of p-nitrophenol to nitrocatechol.  Each inhibitor was diluted by 
taking 5 µL of oil and dissolving it in 100 mL of water to make a stock solution.  
Conditions for the screening assay involved 25 µL of human liver microsomes 
(approximately 1 mg/mL total protein concentration) being incubated at 37°C for 30 
minutes in a reaction mixture containing 100 mM potassium phosphate buffer (pH 7.4), 
50 µM of p-NP, DI water, and various amounts of each oil (ranging from 0.1 µg/mL to 
3.0 µg/mL), added to give a volume of 475 µL.  Each sample was vortexed and placed 
into a hot water bath for one minute prior to the addition of NADPH.  The reaction was 
initiated using 25 µL of NADPH to give a final total volume of 500 µL.   Following the 
30 minute incubation at 37°C the protein was precipitated out with 0.20 mL of 6 % 
perchloric acid and placed on ice for 10 minutes.  Samples were centrifuged for 10 
minutes at 3500 rpm and 460 µL of the clear supernant solution were placed in HPLC 
vials and analyzed by HPLC.   
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II. B. ii. HPLC Analysis 
 The reactions were then analyzed via HPLC.  The HPLC analysis was conducted 
using Shimadzu’s LC-20AT/ Prominence Liquid Chromatography system and the 
samples were detected by the SPC-20A/ Prominence UV/Vis Detector at 340 nm.  Up to 
100 vials were loaded into the Autosampler and a 40 µL sample of each sample was 
injected onto a 150 mm x 4.6 mm C18 HPLC column at a flow rate of 1.0 mL/min.  The 
mobile phases used for this method consisted of two solutions, acetonitrile with 0.5 % 
acetic acid (A) and DI water with 0.5 % acetic acid (B).  The mobile phases wer  set at 
20 % A and 80 % B respectively.  The product, nitrocatechol, had a retention time of 5.60 
minutes under these conditions.  The nitrocatechol peaks from each of the reaction 
samples were integrated to give peak areas, which reflected the relative activities of CYP 
2E1 in human liver samples. 
II. B. iii. Enzyme Kinetics Assay for CYP 2E1 and KI Determination 
 Conditions used for the enzyme kinetics assay involved liver microsomes being 
incubated at 37°C for 30 minutes in a reaction mixture containing a range of p-NP from 
20 µM to 160 µM, 100 mM potassium phosphate buffer (pH 7.4), a specified 
concentration of the inhibitor (between 0.0 and 3.75 mg/mL), and DI water to give a 
volume of 475 µL.  Each sample was vortexed and placed in the hot water bath for one 
minute.  The reaction was initiated with the addition of 25 µL of NADPH to give a final 
total volume of 500 µL.  A control reaction was run with each experiment that was the 
same as above only the inhibitor was replaced with water.  Following the 30 minute 
incubation at 37°C the reaction was quenched and the protein was precipitated out with 
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0.20 mL of 6 % perchloric acid and placed on ice for 10 minutes.  Samples were 
centrifuged for 10 minutes at 3500 rpm and 460 µL of the clear supernant solution was 
placed in HPLC vials to be analyzed by HPLC. 
 The Michaelis Menten model of enzyme kinetics was used in order to determine 
the apparent KI for each oil, expressed as mg oil / mL.  Each KI was found by plotting the 
relative activity (V) vs. substrate concentration ([S]) at a range of increasing 
concentration of p-NP in the presence or absence of inhibitor.  The concentration of 
inhibitor, [I], was chosen based on the conditions of the screening experiments carried
out for each oil where the conditions gave ~50 % inhibition of CYP 2E1.  The Slide 
Write Plus (by Advanced Graphics Software, Inc.) program was used to plot the relative 
activity vs. concentration of p-NP.  The Michaelis-Menten equation (Equation II. 1) was 
used to determine the Vmax, Vmax app, Km, and Km app. 
    Vo = Vmax * [S]   Equation II. 1. 
              Km + [S] 
 
The KI was calculated using the inhibitor concentration and Equation II. 2.   
       K m app = Km (1 + [I]/K I)   Equation II. 2. 
These equations were used because it characterizes a competitive model of inhibition and 
the Vmax app in each case was within 20 % of Vmax demonstrating that a competitive mode 
of inhibition was the primary effect.   
II. C. CYP 3A6 Inhibition: Screening Essential Oils 
 Initially, an assay was developed to determine the amount of oxidized nifedipine 
was produced in the reaction of rabbit liver microsomes with nifedipine.  Microsomes 
were used as the source of CYP 3A4.  Reaction conditions were optimized in order to 
25 
 
generate sufficient product for subsequent inhibition studies.  It was first determined that 
the reactions were producing increasing amounts of oxidized nifedipine with increasing 
amounts of rabbit liver microsomes.  To do this, an assay was developed which included 
increasing amounts of a rabbit liver microsomes (approximately 1 mg/mL total pr ein 
concentration), DI water, potassium phosphate buffer containing 3.3mM MgCl2, (pH 7.4, 
100 mM), and 10 µM nifedipine to give a volume of 412.5 µL.  Each sample was 
vortexed and placed in a 37°C hot water bath for one minute prior to the addition of the 
NADPH-regenerating system, which would give a final total volume of 500 µL.  The 
reaction was initiated with the addition the NADPH-regenerating mixture which 
consisted of a 100 mM potassium phosphate assay buffer containing 3.3mM MgCl2, (pH 
7.4), 33 mM glucose-6-phosphate, NADP+ (1mM), glucose-6-phosphate dehydrogenase 
(1 unit/mL), and DI water.  The NADPH-regenerating system was incubated for 7 
minutes at 37°C prior to it’s’ addition to each of the samples.  Incubation continued for 
one hour at 37°C after the NADPH-regenerating system was added to each sample.  
Controls were run with each experiment that replaced NADPH with water.  Following the 
one hour incubation each sample was quenched with 500 µL of CH2Cl2 and 500 µL each 
of 0.1M Na2CO3 and 0.2 M NaCl.  Each sample was vortexed for 30 seconds and 
centrifuged for 10 minutes to separate the two layers.  The lower organic level was 
removed and inserted into a centrifuged tube and centrifuged under a nitrogen steam until 
dry.  The contents were dissolved in a 500 µL of 64% methanol/36%water solution and 
500 µL samples were placed into HPLC vials and injected into the HPLC for analysis (6).   
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An alternative method was also developed in which reactions were quenched with 
acid and following centrifugation were injected directly onto the HPLC.  To quench the 
reaction, two types of acid were examined 6% perchloric acid and 35% trichloro acetic 
acid.  When using these acids as a quench 200 µL were used to quench the reaction.  
After the one hour incubation each sample was quenched with acid and placed in ice for 
10 minutes then centrifuged at 3000 rpm for 15 minutes.  Samples were then added to 
HPLC vials and loaded into the HPLC for analysis.  
II. C. i. CYP 3A6 Assays and Conditions 
 Enzyme kinetics studies were used to study the effect of the following essential 
oils: Citrus bergamia, Citrus paradisi, Citrus limon, Citrus aurantifolia, Citrus 
reticulata, Citrus aurantium, Citrus sinensis, Citrus aurantium, and Citrus nobilis on 
CYP 3A4.  In addition, the pure compound limonene was also evaluated for its effect on 
CYP 3A4 activity.   
II. C. i. a. Inhibition Screening Assay for CYP 3A6 
Each inhibitor was diluted by taking 5 µL of oil and dissolving it in 100 mL of DI 
water to make a stock solution.  Conditions for the screening assay involved 25 µL of 
rabbit liver microsomes (approximately 1 mg/mL total protein concentration) bei g
incubated at 37°C for 30 minutes in a reaction mixture containing DI water, 100 mM 
potassium phosphate buffer containing 3.3mM MgCl2, (pH 7.4), various amounts of each 
oil (ranging from 0.1 µg/mL to 3.0 µg/mL), and 10 µM nifedipine to give a volume of 
413 µL.  Each sample was vortexed and placed in a 37°C hot water bath for one minute 
followed by the addition of 87 µL of the NADPH-regenerating system to give a final total 
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volume of 500 µL.  The reaction was initiated with the addition the NADPH-regenerating 
system.  The reaction continued for one hour at 37°C after the NADPH-regenerating 
system was added to each sample.  Controls were run with each experiment that replaced 
NADPH with water.  Following the one hour incubation at 37°C the protein was 
precipitated out with the addition of 0.20 mL of 6 % perchloric acid and the resulting 
solutions were placed on ice for 10 minutes.  Samples were centrifuged for 15 minutes at 
3000 rpm and 460 µL of the clear supernant solution was placed in HPLC vials to be 
analyzed by HPLC (6). 
II. C. ii. HPLC Method Development and Analysis 
To analyze the amount of nifedipine oxidized by CYP 3A4, several methods were 
examined using HPLC.  The HPLC analysis was conducted using Shimadzu’s LC-20AT/ 
Prominence Liquid Chromatography system and the samples were detected by the SPC-
20A/ Prominence UV/Vis Detector at 254 nm.  Up to 100 vials were loaded into the 
autosampler and a 40 µL aliquot of each sample was injected onto a 150mm x 3.2 mm 5 
micron C18 column at a flow rate of 0.6 mL/min and a run time of 8 minutes.  Different 
mobile phases were evaluated using a two solvent system consisting of 100% methanol 
(A) and 0.5% acetic acid in DI water (B).  A 50/50 mixture of A and B was initially used, 
but peaks were not sharp or well resolved.  The peaks were joined together, which 
prevented accurate integration of the peak areas.  The mobile phases were then chang d
to a 60/40 solution of A and B giving baseline separation of the product, therefore 
facilitating its accurate quantification.  Standards were used to differentiate between the 
nifedipine and oxidized nifedipine peaks.  The nifedipine eluted off the column at 5.00 
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minutes and was determined by injecting a nifedipine standard solution consisting of 
nifedipine, DI water, and 6 % perchloric acid, into the HPLC.  The product, oxidized 
nifedipine purchased from Oxford Biomedical, gave a retention time of 3.50 minutes 
under these conditions, as determined by injecting an authentic standard solution 
consisting of oxidized nifedipine, DI water, and 6 % perchloric acid, into the HPLC.  The 
oxidized nifedipine peaks from each of the reaction samples were integrated to give the 
relative activities of CYP 3A4 in rabbit liver samples.   
II. D. CYP 2A6 Assays and Conditions 
 Enzyme kinetics studies were used to study the effects of the following citrus 
essential oils, Citrus bergamia, Citrus paradisi, Citrus limon, Citrus aurantifolia, Citrus 
reticulata, Citrus aurantium, Citrus sinensis, Citrus aurantium, and Citrus nobilis on 
CYP 2A6.  An authentic standard of limonene was also evaluated for its effect on CYP 
2A6.   
II. D. i. Initial Screening Assay for CYP 2A6 
The assay that was used to measure inhibition of CYP 2A6 involved the 
hydroxylation of coumarin into 7-hydroxycoumarin.  Each inhibitor was diluted by taking 
5 µL of oil and dissolving it in 100 mL of DI water to make a stock solution.  Conditions 
for the screening assay involved 25 µL of rabbit liver microsomes (source of CYP 2A6), 
which is approximately 1 mg/mL total protein concentration, being incubated at 37°C for 
30 minutes in a reaction mixture containing 100 mM potassium phosphate buffer (pH 
7.4), 80 µM of coumarin, DI water, and various amounts of each oil (ranging from 0.1 
µg/mL to 3.0 µg/mL), added to give a volume of 475 µL.  Each sample was vortexed and 
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placed in the hot water bath for one minute followed by the addition of NADPH.  The 
reaction was initiated using 25 µL of NADPH to give a final total volume of 500 µL.   
Following the 30 minute incubation at 37°C the protein was precipitated out with 0.20 
mL of 6 % perchloric acid and placed on ice for 10 minutes.  Samples were centrifuged 
for 10 minutes at 3500 rpm and 460 µL of each of the clear supernants was placed in 
HPLC vials and analyzed by HPLC (31).   
II. D. ii. HPLC Analysis 
The HPLC analysis was conducted using Shimadzu’s LC-20AT/ Prominence 
Liquid Chromatography system and the samples were detected by the SPC-20A/ 
Prominence UV/Vis Detector at 320 nm.  Up to 100 vials were loaded into the 
Autosampler and a 40 µL aliquot of each sample was injected onto a 150 mm x 3.2 mm 5 
micron C18 column with a flow rate of 0.6 mL/min and a run time of 4 minutes.  The 
mobile phases used for this method consisted of two solutions, 100% methanol (A) and 
94 % DI water, 5.0 % methanol and 1.0% acetic acid (B).  The system was run with an 
isocratic mobile phase consisting of phases 55 % A and 45 % B.  Standards were used to 
differentiate between the coumarin and 7-hydroxycoumarin peaks.  The coumarin had a 
retention time of 1.97 minutes and was determined by injecting a coumarin standard 
solution consisting of coumarin, DI water, and 6 % perchloric acid, into the HPLC.  The 
product, 7-hydroxycoumarin, had a retention time of 1.65 minutes and was determined by 
injecting an authentic standard consisting of 7-hydroxycoumarin, DI water, and 6 % 
perchloric acid.  The 7-hydroxycoumarin peaks from each of the reaction samples were 
integrated to give relative activities of CYP 2A6 in rabbit liver samples.   
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II. D. iii. Enzyme Kinetics Assay for CYP 2A6 and KI Determination 
 Conditions used for the enzyme kinetics assay involved 25 µL of rabbit liver 
microsomes (approximately 1 mg/mL total protein concentration) being incubated at 
37°C for 30 minutes in a reaction mixture containing a range of coumarin concentrations 
from 2 µM to 20 µM, 100 mM potassium phosphate buffer (pH 7.4), an amount of 
inhibitor that gave rise to ~50 % inhibition of CYP 2A6 in the screening assays, and DI 
water to give a volume of 475 µL.  Each sample was vortexed and placed in the 37°C 
water bath for one minute prior to the addition of NADPH.  The reaction was initiated 
with the addition of 25 µL of NADPH to give a final total volume of 500 µL.  A control 
reaction was run with each experiment that was the same as above only the inhibitor was 
replaced with water.  Following the 30 minute incubation at 37°C the reaction was 
quenched with 0.20 mL of 6 % perchloric acid and placed on ice for 10 minutes to 
precipitate the protein.  Samples were centrifuged for 10 minutes at 3500 rpm and 460 µL 
of the clear supernant solution was placed in HPLC vials to be analyzed by HPLC. 
Michaelis-Menten plots were used in order to determine the KI for each oil 
examined.  Each KI was found by plotting the V vs. [S] at a range of increasing 
concentration of coumarin in the presence or absence of inhibitor.  The concentration of 
inhibitor, [I], was chosen based on the conditions of the screening experiments carried
out for each oil where the conditions gave ~50 % inhibition of CYP 2A6.  The Slide 
Write Plus (by Advanced Graphics Software, Inc.) program was used to plot the relative 
activity vs. concentration of coumarin.  The Michaelis-Menten equation (Equation II. 1) 
was used to determine the Vmax, Vmax app, Km, and Km app.  The KI was calculated using the 
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inhibitor concentration and Equation II. 2.  These equations were used because the Vmax 
app was within 20 % of Vmax for of each experiment demonstrating a predominantly 
competitive mode of inhibition and these equations characterize a competitive model of 
inhibition. 
III. E. Limonene Analysis 
 Limonene was found to be present in all of the citrus oils, and was therefore 
chosen as a potential candidate for the chemical inhibitor present in the oils.  The GCMS 
analysis was conducted using a Shimadzu’s GCMS-QP2010S system.  GCMS was used 
to determine the limonene content of each of the oils.  To determine the amount of 
limonene in each of the oils a series of dilutions of limonene in methanol were prepared 
and a 1.0 µL sample of each solution was injected into a Shimadzu QP2010S  GCMS 
system to generate a limonene standard curve.  The limonene peak had a retention time of 
9.90 minutes and was manually integrated in order to correlate peak area with total 
concentration.  The GCMS conditions consisted of an initial column oven temperature of 
40°C that increased 1.7°C per second until it reached 280°C which was the injection 
temperature at 3 minutes.  The injection mode was split and the total experiment was 27 
minutes.  The concentration in each sample was calculated based on weight, and this was 
plotted against the peak area given for that sample giving a standard curve for limonene.  
A 1.0 µL aliquot of each of the oils was dissolved in 5 mL of methanol and a 1 µL 
sample was injected into the GCMS.   The limonene peak from each of the samples was 
integrated to give a relative peak area of each solution.  The limonene peak area was 
compared with the limonene standard curve to give an estimated concentration of 
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limonene in each of the oils.  To determine mathematically a more accurate concentration 
of limonene in each of the oils Equation II. 3 (generated using the standard curve data) 
was used along with the relative peak area of limonene determined for each of the oils.     
       y = 18963x – 5386.3   Equation II. 3. 
In Equation II. 3 (y) represents the relative peak area of limonene and (x) represents the 
concentration of limonene. 
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CHAPTER III 
RESULTS AND DISCUSSION 
 
III. A. Inhibition of CYP 2E1 by Citrus Essential Oils 
 The interaction of CYP 2E1 with citrus essential oils led to inhibition of the 
enzyme.  This was shown using an enzymatic assay for the oxidation of p-nitrophenol to 
nitrocatechol with HPLC detection.  The initial screening experiments were successful in 
demonstrating an increased inhibitory response with increasing concentration of the oil 
(dose-response), and in assessing relative potency of the oils with regard to CYP2E1 
inhibition.  The citrus essential oil samples were initially prepared by diluting 5 µL pure 
oil into 100 mL of DI water.  Each of the oils were included in the reaction with 50 µM p-
NP in increasing concentration from 0.0 µg/mL to 3.8 µg/mL.  Figure III. 1 shows the 
inhibition of CYP 2E1 by the citrus essential oils of bergamot, grapefruit, lemon, lime, 
and mandarin.  As seen in this figure, of these five oils, grapefruit oil inhibited the 
activity of CYP 2E1 the greatest with >50 % inhibition at a concentration lower than 2.5 
µg/mL.  Lemon oil also inhibited the activity of CYP 2E1 with >50 % inhibition at a 
concentration lower than 2.5 µg/mL, however, lemon was not as potent as grapefruit.  
Lime and bergamot oils inhibited >50 % at a concentration around 3.8 µg/mL.  Mandarin 
oil was the only oil in this figure that didn’t inhibit the activity of CYP 2E1 more than 50 
% at concentrations as high as 3.8 µg/mL.      
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Figure III. 1:  Graph of percent activity of CYP 2E1 using human liver microsomes in 
the presence of 50 µM p-nitrophenol and different essential oils from 0.0 µg/mL to 3.8 
µg/mL. 
 
 
 
Since the main compound found in grapefruit oil is limonene it was proposed that 
limonene might be the cause of the inhibition of the activity of CYP 2E1.  Literature 
results of the limonene content found in these citrus essential oils, Table I. 1, showed that 
limonene is found in all of the citrus essential oils used for inhibition studies for CYP 
2E1.  Figure III. 2 shows the inhibition of CYP 2E1 by the citrus essential oils of neroli, 
orange, petitgrain, tangerine, and limonene.  As seen in this figure, of these five oils, 
orange oil inhibited the activity of CYP 2E1 the greatest with >50 % inhibition at a 
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concentration lower than 2.5 µg/mL.  Tangerine oil, petitgrain oil, and neroli oil all
inhibited the activity of CYP 2E1 by >50 % at concentrations lower than 2.5 µg/mL, 
however, orange oil was the most potent.  As seen in Figure III. 2, limonene did not 
inhibit the activity of CYP 2E1 by 50 % even at the highest concentrations of 3.8 µg/mL.   
Based on initial comparison of the screening data for all nine of the citrus essential oils, 
grapefruit oil appeared to be the most potent oil inhibiting the activity of CYP 2E1 by 
~70 % at concentrations lower than 2.5 µg/mL.  Mandarin oil was found to be the least 
potent oil to inhibit CYP 2E1 activity only showing about 30 % inhibition of CYP 2E1 
activity at a concentration of 3.8 µg/mL.  Given the occurrence of limonene in all of the
citrus oils studied, we sought to link the inhibition of CYP 2E1 by the citrus oils to the 
presence of this monoterpeniod compound.  To make this correlation, a standard curve 
was prepared for limonene using GCMS as described later in the chapter.   
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Figure III. 2:  Graph of percent activity of CYP 2E1 using human liver microsomes in 
the presence of 50 µM p-nitrophenol and different essential oils from 0.0 µg/mL to 3.8 
µg/mL. 
 
 
III. A. i. Enzyme Kinetics Analysis 
 A more precise characterization of the inhibitory effects of there citrus essential 
oils on the activity of CYP 2E1 was achieved via kinetics analysis using the Michaelis-
Menten model of enzyme kinetics and inhibition.  The kinetics experiments were carried 
out using 5 different p-NP concentrations ranging from 20 µM to 160 µM in the presence 
and absence of inhibitor in duplicate or triplicate to ensure reproducible.  The 
concentration of oil selected for each experiment was based on the results of the initial 
screening studies.  A concentration was selected where ≥ 50 % inhibition was observed 
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under the standard conditions used for screening.  Human microsomes were incubated 
with one of the nine oils examined and p-NP using different concentrations of substrate 
ranging from 20 µM to 160 µM.  The relative activities (as determined by integration of 
the peak area for the product nitrocatechol) were plotted against the concentration of p-
NP as in a Michaelis-Menten model.  Based on the observation that the Vmax for the 
control experiments and those with inhibitor present were virtually the same, a 
competitive model of inhibition was used to calculate a KI for each of the nine oils 
examined (Table III. 1), in order to generate a quantitative measure of the inhibition.    
 
Essential 
Oil 
K I 
(µg/mL) 
Error 
(µg/mL) Km Km app Vmax Vmax app 
Grapefruit 9 ± 1.6 14 36 92 118 
Orange  8 ± 2.5 15 40 118 104 
Tangerine 4.3 ± 0.20 14 55 97 106 
Mandarin 7 ± 1.0 15 82 99 102 
Lemon 8 ± 0.34 16 43 146 118 
Lime 10 ± 2.5 18 82 99 88 
Bergamot 6.4 ± 1.1 10 64 92 103 
Neroli 14 ± 2.4 17 48 123 105 
Petitgrain 7.6 ± 0.43 15 64 106 119 
 
 
Table III. 1:  Averaged KI values and error values calculated for CYP 2E1 inhibition 
activity by the nine citrus essential oils examined.  Also included are Km, Km app, Vmax and 
Vmax app values for all of the oils.   
 
 
Of the nine oils examined using the Michaelis-Menten model, tangerine oil was found to 
be the most potent inhibitor based on its calculated KI.  To illustrate how the values in 
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Table III. 1 were obtained, sample kinetics plots for tangerine and neroli oil are shown in 
Figures III. 3 and III. 4.  Figure III. 3 shows a representative experiment shown as a 
Michaelis-Menten plot for tangerine oil.  Based on the data shown in the Michaelis-
Menten plot (Figure III. 3), a Vmax and KM were calculated in the absence and presence 
of tangerine oil.  Based on the observation that Vmax was unaffected, the competitive 
model of inhibition was used to calculate a KI of 4.04 µg/mL for tangerine oil.  For 
example, Km was 14.48 and Km app was 58.95.  The ratio of Km / Km app was set equal to α 
and substituted into Equation III. 1.   
 α = 1 + [I] / KI    Equation III. 1.  
Of the nine oils examined during screening neroli was found to be the least potent 
inhibitor based on Michaelis-Menten experiments.  Therefore the corresponding data for 
this α are also included.  Figure III. 4 shows a representative experiment shown as a the 
Michaelis-Menten plot for neroli oil.  Based on the data shown in the Michaelis-Menten 
plot (Figure III. 4), a Vmax and Km were calculated in the absence and presence of neroli 
oil.  Once again Vmax was unaffected by the presence of the oil, whereas a significant 
effect was observed on Km, the competitive model of inhibition was used to calculate a KI 
of 11.48 µg/mL for neroli oil.   
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Figure III. 3:  Plot of area vs. p-nitrophenol (µM) concentration in the presence (pluses) 
and absence (triangles) of tangerine oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 20 µM to 160 µM, and NADPH. 
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Figure III. 4:  Plot of area vs. p-nitrophenol (µM) concentration in the presence (pluses) 
and absence (triangles) of neroli oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 20 µM to 160 µM, and NADPH. 
 
 
 
III. B. Inhibition of CYP 3A6 by Citrus Essential Oils 
  The importance of CYP 3A4 in the metabolism of pharmaceuticals prompted the 
current investigation into the inhibitory effect of citrus oils on this CYP 450 isoform.  
Ortiz de Montellano et al (13) have reported that 30 % of all drugs are metabolized by 
human CYP 3A4, and the interaction between CYP 3A4 and grapefruit juice, and the 
potential for adverse drug interactions are well documented (13).  The interaction of CYP 
3A6 with citrus essential oils lead to very poor inhibition of the enzyme.  This was shown 
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using the enzymatic assay for the oxidation of nifedipine to oxidized nifedipine with 
HPLC detection.  Our initial efforts focused on development of an assay to determine the 
optimal conditions for measuring activity of CYP 3A6 in rabbit liver microsomes (source 
of CYP 3A6).  The rabbit liver was chosen as a model to look at inhibition of 3A family 
enzymes.  The rabbit liver CYP 3A6 is closely related to the human CYP 3A4.   
The method reported in the literature for the CYP 3A-dependent nifedipine 
oxidation involved a solvent extraction step prior to HPLC analysis, which is time 
consuming and difficult for high through-put analysis (6).  We sought to improve this 
assay by finding a way to eliminate the extraction step, which would make the assay 
faster and easier to use.  Several different quenching methods were evaluated in an 
attempt to eliminate extraction and streamline the assay.  Initially, 35 % trichloro acetic 
acid was used to terminate the CYP450 reaction, however the data observed for the 
samples were somewhat inconsistent.  Next, the addition of a 6.0 % perchloric acid 
solution was used to quench the reaction and the data observed for these samples were 
similar to those obtained using the extraction method.  As a result, using 6.0 % perchloric 
acid to quench the reactions followed by protein precipitation and centrifugaion gave 
better reproducibility and was less time consuming than the extraction method.  
Therefore, this non-extraction method was adopted for all subsequent studies.   
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Figure III. 5:  Graph of the amount of oxidized nifedipine produced by rabbit liver 
microsomes, a source of CYP 3A6, with increasing amounts of microsomes from 0.02 
µg/mL to 0.08 µg/mL, 10 µM nifedipine, and a NADPH-regenerating system.   
 
Figure III. 5 shows the amount of oxidized nifedipine that was produced when the 
reaction contained either 0.02 µg/mL, 0.04 µg/mL, 0.06 µg/mL, or 0.08 µg/mL of rabbit 
liver microsomes (approximately 1 mg/mL total protein concentration).  The relationship 
between the amount of oxidized nifedipine produced and the amount of microsomes 
present in the reaction is approximately linear up to 0.06 mg/mL of microsomes, 
suggesting that above 0.06 mg/mL one of the reaction components may have been fully 
consumed.   
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 High Performance Liquid Chromatography was used to analysis each sample.  All 
samples were run on a 150 mm x 3.2 mm 5 micron C18 column and detection was set at a 
wavelength of 340 nm with the flow rate set at 0.6 mL/min and a run time of 8 minutes.  
To analyze the amount of oxidized nifedipine by CYP 3A6 several methods were 
examined using HPLC.  Several different mobile phases were evaluated to establish the 
best chromatogram results for the separation of oxidized nifedipine and nifedipine.  The 
two solvent system mobile phases that were used to evaluate the activity of CYP 3A6 
consisted of 100 % methanol (A) and 0.5 % acetic acid in DI water (B).  The first mobile 
phase tested consisted of a 50/50 mixture of A and B, but product and reactant peaks 
were not sharp and were too close together.  The peaks were joined together and a proper 
integration of the oxidized nifedipine peak was not possible.  The mobile phases were 
then changed to a 60/40 solution of A and B, respectively, and the peaks were well 
resolved and easily integrated.   
Figure III. 6 shows an HPLC chromatogram of both nifedipine and oxidized 
nifedipine standards.  The nifedipine standard contained 10 µM nifedipine, DI water, and 
2 % perchloric acid.  The peak seen at about 290 seconds was determined to be 
nifedipine.  The peak with the retention time around 200 seconds was observed for the 
oxidized nifedipine standard which contained an authentic sample of oxidized nifedipine, 
DI water, and 2 % perchloric acid.  This peak was also observed in reactions with rabbi 
liver microsomes, nifedipine and NADPH was used to quantify CYP 3A6 activity in the 
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rabbit microsomes.  
 
Figure III. 6:  Oxidized nifedipine and nifedipine standards HPLC chromatograms 
containing either oxidized nifedipine or 10 µM nifedipine and DI water and 2 % 
perchloric acid, but lacked NADPH. The peak at 190 sec. was identified as oxidized 
nifedipine. The smaller peak at 270 sec. was identified as nifedipine. 
 
Initially, as with the CYP 2E1 assay, each oil was screened for its ability to inhibit 
CYP 3A6.  The screening experiment was successful in producing consistent results for 
all the essential oils examined.  Each citrus essential oil was examined by visual 
inspection of the dose response data in either duplicate or triplicate to ensure 
reproducibility.  The citrus essential oils were initially diluted by taking 5 µL and 
dissolving it in 100 mL of DI water.  Each of the oils were included in the reaction with 
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10 µM nifedipine in increasing concentration from 0.0 µg/mL to 3.0 µg/mL.  Figure III. 
7 shows the inhibition of CYP 3A6 by the citrus essential oils of bergamot, grapefruit, 
lemon, lime, and mandarin.  As seen in this figure, of these five oils, lemon oil inhibited 
the activity of CYP 3A6 the greatest but did not reach >50 % inhibition at concentrations 
as high as 3.0 µg/mL.  Mandarin and bergamot oils also inhibited the activity of CYP 
3A6 however >50 % inhibition at concentrations as high as 3.0 µg/mL was not reach.  
None of the five oils shown in this figure reached 50 % inhibition of CYP 3A6 activity at 
concentrations as high as 3.0 µg/mL.  Interestingly, for all of the oils except lime, there 
appeared to be a modest increase in activity at the lowest concentration of oil, followed 
by a return to 100 % or slight inhibition at the higher concentrations.  Clearly, based on 
these findings, none of the first 5 oils tested appeared to interact strongly with the rabbit 
CYP 3A6 isoform.     
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Figure III. 7:  Graph of percent activity of CYP 3A6 using rabbit liver microsomes in 
the presence of 10 µM nifedipine and different essential oils from 0.0 µg/mL to 3.0 
µg/mL. 
 
Figure III. 8 shows the inhibition of CYP 3A6 by the citrus essential oils of neroli, 
orange, petitgrain, tangerine, and limonene.  Orange oil was the only oil that we were 
unable to obtain reproducible data for.  The other four oils in the figure showed very littl  
inhibition on the activity of CYP 3A6, not reaching 50 % inhibition at concentrations as 
high as 3.0 µg/mL.  Again, the oil of neroli appeared to stimulate activity at the lowest 
concentration.  Several explanations may account for this modest stimulation.  For 
example, it has been reported that radical scavenging can affect the activity of CYP 3A4 
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(27).  It is thought that antioxidants interact with the free radical chain of oxidation by 
donating a hydrogen atom and forming a stable product.  Basavaraj Girennavar et al have 
shown that bergaptol and geranylcoumarin, isolated from grapefruit juice, act as r dical 
scavengers when tested against CYP 3A4 enzymes.   
 The results that were observed for the inhibition of CYP 3A6 activity experiments 
suggested that the citrus essential oils tested had only modest effect on the activity of 
CYP 3A4.  The general lack of inhibition of CYP 3A6 by the oils could be due to the 
small size of most of the oils constituents, as monoterpenes, relative to the size of CYP 
3A6’s active site.  This is interpreted to suggest that citrus essential oils wou d gave no 
significant impact on the human CYP 3A4 and thus should pose no threat of adverse drug 
interactions.   
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Figure III. 8:  Graph of percent activity of CYP 3A6 using rabbit liver microsomes in 
the presence of 10 µM nifedipine and different essential oils from 0.0 µg/mL to 3.0 
µg/mL. 
 
 
III. C. Inhibition of CYP 2A6 by Citrus Essential Oils 
The interaction of CYP 2A6 with citrus essential oils led to relatively strong 
inhibition of the enzyme.  This was shown using an enzymatic assay for the 
hydroxylation of coumarin into 7-hydroxylation with HPLC detection. This assay was 
developed in our lab for the purpose of high throughput HPLC analysis of CYP 2A6 
inhibitors.  Figure III. 9 shows an HPLC chromatogram of both coumarin and 7-
hydroxycoumarin combined.  The coumarin standard contained 80 µM coumarin, DI 
49 
 
water, and 2 % perchloric acid.  The peak seen at about 115 sec. was determined to be 
coumarin.  The peak with the retention time around 95 sec. was observed for the reaction 
mixture that was the 7-hydroxycoumarin standard which contained 1.0 µM 7-
hyrdoxycoumarin, DI water, and 2 % perchloric acid.   
 
Figure III. 9:  7-Hydroxycoumarin and coumarin standards HPLC chromatograms 
containing either 1.0 mM 7-hydroxycoumarin or 1.0 mM nifedipine and DI water and 6 
% perchloric acid, but lacked NADPH. The peak at 95 sec. was identified as 7-
hydroxycoumarin. The smaller peak at 115 sec. was identified as coumarin. 
 
The interaction of CYP 2A6 with certain citrus essential oils led to relatively 
potent inhibition of the enzyme when compared with CYP 3A4.  This was shown using 
an initial screening of the oils for their inhibition of the enzymatic activity of rabbit liver 
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microsomes in the hydroxylation of coumarin into 7-hydroxycoumarin.  The initial 
screening experiment gave reproducible results for all the essential oils examined when 
carried out in duplicate or triplicate.  Each citrus essential oil was examined initially by 
visual inspection of the dose response.  The citrus essential oils were initially d luted by 
taking 5 µL of the oil and dissolving it in 100 mL of DI water.  Each of the oils were 
included in the reaction with 80 µM coumarin in increasing concentration from 0.0 
µg/mL to 3.0 µg/mL.   
To illustrate the effect that lime and bergamot oil have on the activity of CYP 
2A6, chromatograms from the screening experiments of the two oils are presented in 
Figure III. 10.  These chromatograms represent the initial inhibition screening data used 
for the screening of the lime oil conducted on CYP 2A6 activity.  In order to better 
visualize the effect that lime oil had on the activity of CYP 2A6 only the 7-
hyrdoxycoumarin peaks are shown in the figure.  The control line represents the con rol 
experiment in which no inhibitor was present.  The 0.1 µg/mL line is representative of the 
data when the inhibitor concentration was 0.1 µg/mL, the 0.5 µg/mL line if when the 
inhibitor concentration was at 0.5 µg/mL, the 2.0 µg/mL line is when the inhibitor 
concentration was at 2.0 µg/mL, and the 3.0 µg/mL line is when the inhibitor 
concentration was at 3.0 µg/mL.  As seen in this figure, lime oil showed a >50 % 
inhibition of the activity of CYP 2A6 at only 0.5 µg/mL.  Figure III. 11 shows a 
chromatogram of the initial inhibition screening data used for the screening inhibition of 
the bergamot oil conducted on CYP 2A6 activity.  Again, to better visualize the effect 
that bergamot oil had on the activity of CYP 2A6 only the 7-hyrdoxycoumarin (product) 
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peaks are shown in the figure.  The control line represents the control experiment in 
which no inhibitor was present.  The 0.1 µg/mL line is representative of the data when 
the inhibitor concentration was 0.1 µg/mL, the 0.5 µg/mL line if when the inhibitor 
concentration was at 0.5 µg/mL, the 2.0 µg/mL was when the inhibitor concentration was 
at 2.0 µg/mL, and the 3.0 µg/mL line was when the inhibitor concentration was at 3.0 
µg/mL.  As with bergamot, lime oil shows >50 % inhibition of the activity of CYP 2A6 
at only 0.5 µg/mL.   
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Figure III. 10:  Chromatogram of the screening data used for the initial screening 
inhibition experiment of lime oil on CYP 2A6 activity.  Reactions contained rabbit liver 
microsomes, DI water, 80 µM coumarin, a range of inhibitor from 0.0 µg/mL , 0.1 
µg/mL, 0.5 µg/mL, 2.0 µg/mL, and 3.0 µg/mL, and NADPH. 
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Figure III. 11:  Chromatogram of the screening data used for the initial screening 
inhibition experiment of bergamot oil on CYP 2A6 activity.  Reactions contained rabbit 
liver microsomes, DI water, 80 µM coumarin, a range of inhibitor from 0.0 µg/mL, 0.1 
µg/mL, 0.5 µg/mL, 2.0 µg/mL, and 3.0 µg/mL, and NADPH. 
 
 
 
Figure III. 12 shows the inhibition of CYP 2A6 by the citrus essential oils of bergamot, 
grapefruit, lemon, lime, and mandarin.  As seen in this figure, of these five oils, lime oil 
inhibited the activity of CYP 2A6 the greatest with >50 % inhibition at a concentrations 
as low as 0.5 µg/mL.  Bergamot oil also inhibited the activity of CYP 2A6 at a 
concentration of 0.5 µg/mL.  Mandarin oil and grapefruit oil were the only oils, shown in 
this figure, that did not inhibit the activity of CYP 2A6 by 50 % inhibition at a 
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concentration as high as 3.0 µg/mL.  Lemon oil inhibited the activity of CYP 2A6 by 50 
% at a concentration around 1.3 µg/mL.   
 
 
Figure III. 12:  Graph of percent activity of CYP 2A6 using rabbit liver microsomes, 
source of CYP 2A6, in the presence of 80 µM coumarin and different essential oils from 
0.0 µg/mL to 3.0 µg/mL. 
 
Figure III. 13 shows the inhibition of CYP 2E1 by the citrus essential oils of neroli, 
orange, petitgrain, tangerine, and limonene.  As seen in this figure, petitgrain oil inhibited 
the activity of CYP 2A6 the greatest with >50 % inhibition at a concentration of 2.0 
µg/mL.  Neroli oil and orange oil showed moderately good inhibition of the activity of 
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CYP 2A6 with 50 % inhibition at a concentration of 1.3 µg/mL however they were not as 
potent of an inhibitor of CYP 2A6 as bergamot oil and lime oil.  Tangerine oil was the 
least potent inhibitor in this figure, showing little inhibition by only reaching >50 % 
inhibition of CYP 2A6 activity at a concentration of about 2.5 µg/mL.  Limonene showed 
moderately good inhibition of CYP 2A6 activity, reaching >50 % inhibition at a 
concentration of about 1.3 µg/mL.  All of these observations point to bergamot and lime 
oil being the most potent inhibitors of CYP 2A6.   
 
 
 
Figure III. 13:  Graph of percent activity of CYP 2A6 using rabbit liver microsomes, 
source of CYP 2A6, in the presence of 80µM coumarin and different essential oils from 
0.0 µg/mL to 3.0 µg/mL.  
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III. C. i. Enzyme Kinetics Analysis for CYP 2A6 
 To better characterize the effects of the bergamot and lime citrus essential oils on 
the activity of CYP 2A6 each of them were examined using the Michaelis-Menten model 
of enzyme kinetics and inhibition.  The experiments were carried out in the presence and 
absence of inhibitor in duplicate or triplicate for demonstration of reproducibility.  Rabbit 
liver microsomes, the source of CYP 2A6, were incubated with one of oils, diluted 5 µL 
into 100 mL of DI water, and 80 µM coumarin using different concentrations of substrate 
ranging from 0.01 µM to 0.10 µM.  The amount of inhibitor used for each oil was 
determined using the screening assay for that given oil where it gave ~50 % inhibitio  of 
CYP 2A6 activity, which in both cases was 0.5 µg/mL.  The relative activities were 
plotted against the concentration of coumarin as in a Michaelis-Menten model.  Based on 
the observation that the Vmax between the control experiment and the experiment with 
inhibitor present was unaffected, a competitive model of inhibition and Equation II. 1 
and Equation II. 2 were used to calculate a KI for each the oils examined (Table III. 2).   
Since bergamot and lime were more potent than the other oils used in the screening study, 
only these two oils were evaluated for KI determination.   
Essential Oil KI  µg/mL 
Bergamot 0.81 
Lime 1.4 
 
Table III. 2:  K I values calculated for CYP 2A6 inhibition activity by bergamot and lime 
citrus essential oils. 
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Of the two oils examined bergamot oil was found to be the most potent inhibitor based on 
the kinetics data.  Figure III. 14 shows a representative experiment shown as a 
Michaelis-Menten plot for lime oil.  Based on the data shown in this plot (Figure III. 
14), a Vmax and KM were calculated in the absence and presence of lime oil.  Once again 
Vmax appeared to be unaffected so the competitive model of inhibition and Equation II. 1 
and Equation II. 2 were used to calculate a KI of 1.4 µg/mL for lime oil.  The essential 
oil lime was found to be a less potent inhibitor than bergamot oil based on Michaelis-
Menten experiment shown in Figure III. 15.  Based on the data in this Michaelis-Menten 
plot (Figure III. 15), a Vmax and KM were calculated in the absence and presence of 
bergamot oil.  The observed Vmax was once again unaffected by the presence of the oil 
and the competitive model of inhibition used to calculate a KI of 0.81 µg/mL for 
bergamot oil. 
 As stated previously, tobacco use has been associated with different types of 
cancers for quite some time.  Cancers of the lung, larynx, mouth, esophagus, kidneys, and 
urinary tract have all been linked to tobacco use.  It has been shown that CYP450 
enzymes are able to metabolize tobacco carcinogens into DNA-binding metabolites (22).   
CYP 2A6 enzymes are the main catalyst involved in the metabolism of nicotine to 
cotinine via 3’-hyrdoxylation (13).   The inhibition of CYP 2A6 has recently been 
identified as a possible therapeutic approach to smoking cessation, therefore giving 
significant importance to bergamot and lime oils and the compounds found in them.  
Bergamot and lime oils both contain the compound limonene and also both contain the 
compounds geranial and linalol.  It is proposed that another compound found in these oils 
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may react with limonene to cause the inhibition of CYP 2A6 activity since both oils 
presented low concentrations of limonene compared to the other oils examined.   
 
Figure III. 14:  Plot of area vs. coumarin concentration, best representative, in the 
presence (pluses) and absence (triangles) of lime oil (0.50 µM).  Reactions contained 
inhibitor, rabbit liver microsomes, a range of substrate concentrations from 0.01 mM to
0.10 mM, and NADPH. 
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Figure III. 15:  Plot of area vs. coumarin concentration, best representative, in the 
presence (pluses) and absence (triangles) of bergamot oil (0.50 µM).  Reactions 
contained inhibitor, rabbit liver microsomes, a range of substrate concentrations from 
0.01 mM to 0.10 mM, and NADPH. 
 
 
III. D. Limonene Analysis 
 The GCMS analysis was conducted using a Shimadzu’s GCMS-QP2010S system.  
GCMS was used to determine the limonene content of limonene standards and each of 
the oils examined.  To determine the amount of limonene in each of the oils a series of 
dilutions of limonene in methanol were prepared and a 1 µL sample of each solution was 
injected into a Shimadzu GCMS system to generate a limonene standard curve (Figur  
III. 16).  The limonene peak had a retention time of 9.90 minutes and was able to be 
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manually integrated using parameters based on its molecular weight of 136 g/mol to give 
a total ion concentration of limonene in each sample.  Based on the weight of a 10 µL 
sample of the limonene used in the experiments the concentration in each sample was 
determined and plotted against the average peak area determined for that sample. Figure 
III. 16 shows the plot of the average limonene peak area vs. the concentration of 
limonene in each dilution along with the data collected for each of the nine oils 
examined.  The average limonene peak area was plotted onto the limonene standard curve 
to give an estimated concentration of limonene in each of the oils (Figure III. 16).  Each 
oil is represented by a different number in the figure, bergamot is 1, grapefruit is 2, lemon 
is 3, lime is 4, mandarin is 5, neroli is 6, orange is 7, and tangerine is 8.  Petitgrain oil 
was the only oil that a limonene peak was unable to be detected in which is expected 
when compared with the literature results of only have about a 1-2% limonene content 
(Table I. 1).   
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Figure III. 16:  Limonene standard curve showing the average peak area of limonene 
content in each standard dilution vs. total calculated limonene content.  Oils are 
integrated into plot showing an estimated value for total limonene content in each oil, 
bergamot (1), grapefruit (2), lemon (3), lime (4), mandarin (5), neroli (6), orange (7), and 
tangerine (8). 
 
To determine mathematically a more accurate concentration of limonene in ach of the 
oils Equation II. 3 was used to calculate the total limonene concentration in each of the 
oils along with the average peak area of limonene for each of the oils.   
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Oil 
Average 
Peak Area 
% 
Error 
[Limonene] 
(mM)  
Limonene  144674 2.8 7.72  
Limonene 1:2 Dilution 59669 6.8 3.86  
Limonene 1:4 Dilution 31298 4.7 1.93  
Limonene 1:8 Dilution 14596 17 0.965  
Limonene 1:16 Dilution 6474 15 0.483  
         
Oil 
Average 
Peak Area 
% 
Error 
[Limonene] 
(mM) 
% 
Limonene 
Bergamot 60210 11 3.46 45 
Grapefruit 143292 4.6 7.84 101 
Lemon 75051 1.6 4.24 55 
Lime 65765 0.33 3.75 49 
Mandarin 666452 6.2 3.79 49 
Neroli 73148 0.56 4.14 54 
Orange  120685 2.3 6.65 86 
Petitgrain …… …… …… …… 
Tangerine 106873 3.5 5.92 77 
 
Table III. 3:  Average peak area values for the limonene content in each limonene 
standard dilution and in each of the oils examined, percent error for each experiment, and 
total calculated limonene concentration for each sample in mM and percent.   
 
 
Table III. 3 shows the data collected for the limonene standard curve as well as the data 
collected for each of the nine oils examined along with the percent error for each 
experiment and the calculated limonene concentration in each sample in mM and percent.   
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CHAPTER IV 
CONCLUSION 
 
The p-nitrophenol oxidation, the nifedipine oxidation, and the coumarin 7-
hydroxylation assays have all become important experiments used to probe the activity of 
CYP 2E1, CYP 3A4, and CYP 2A6 in the presences of citrus essential oils.  Citrus 
essential oils have been shown in inhibit the activity of CYP 2E1 at concentrations lower 
than 2.5 µg/mL of inhibitor.  Grapefruit oil and orange oil showed to inhibit the activity 
of CYP 2E1 the greatest of the nine oils examined.  None of the oils seemed to inhibit the 
activity of CYP 3A4 which could be explained by the size of its active site vs. the size of 
the components in the oils.  Citrus essential oils have been shown to inhibit the activity of 
CYP 2A6 at concentrations as low as 0.5 µg/mL of inhibitor.  Bergamot oil and lime oil 
showed to inhibit the activity of CYP 2A6 the greatest of the nine oils examined.   
As predicted the citrus essential oils with the greatest concentration of limonene 
would inhibit the activity of CYP 2E1 the most.  As shown by the amount of limonene 
present in each of the oils examined grapefruit and orange oils had the highest 
concentrations of limonene and were the most potent inhibitors of the activity of CYP 
2E1.  However, the inhibitors ability to inhibit the activities of CYP 2E1 and 2A6 is 
attributed to not only the limonene content but also another component that is present in 
the oils.  This conclusion is based on the fact that when tested as an inhibitor limonene 
was not as potent of an inhibitor as grapefruit oil, orange oil, bergamot oil, and lime oil 
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were on the activities of CYP 2E1 or CYP 2A6.  Limonene did not inhibit the activity of 
CYP 2E1 by >50 % at the highest concentrations of 3.8 µg/mL whereas grapefruit oil and 
orange oil inhibited the activity of CYP 2E1 by >50 % at concentrations lower than 2.5 
µg/mL.  Limonene showed moderately good inhibition of CYP 2A6 activity, reaching a 
>50 % inhibition at a concentration of about 1.3 µg/mL, however, bergamot oil and lime 
oil both inhibited the activity of CYP 2A6 at concentrations as low as 0.5 µg/mL.   
Based on other observations and literature research the inhibition CYP 2E1 and 
CYP 2A6 activity by grapefruit oil, orange oil, bergamot oil, and lime oil could be due to 
the presence of limonene as well as the presence of linalol in the oils.  Cytochrome P450 
inhibition has been shown by citrus essential oils and further research with these oils 
would lead to a better understanding on their impact on the metabolism, 
pharmacodynamics, and drug-drug interactions that these citrus essential oils may have. 
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